These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 313366)

  • 1. Role of complement in the expression of delayed-type hypersensitivity in rats: studies with cobra venom factor.
    Jungi TW; McGregor DD
    Infect Immun; 1979 Mar; 23(3):633-43. PubMed ID: 313366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delayed hypersensitivity reactions to Listeria monocytogenes in rats decomplemented with cobra factor and in C5-deficient mice.
    Jungi TW; Pepys MB
    Immunology; 1981 Jun; 43(2):271-9. PubMed ID: 6788681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Required early complement activation in contact sensitivity with generation of local C5-dependent chemotactic activity, and late T cell interferon gamma: a possible initiating role of B cells.
    Tsuji RF; Geba GP; Wang Y; Kawamoto K; Matis LA; Askenase PW
    J Exp Med; 1997 Oct; 186(7):1015-26. PubMed ID: 9314551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-cell co-operation in the mediation of acquired resistance to Listeria monocytogenes.
    Chen-Woan M; Sajewski DH; McGregor DD
    Immunology; 1985 Sep; 56(1):33-42. PubMed ID: 3876276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of delayed hypersensitivity in mice by cobra venom factor.
    Bloksma N; van Dijk H; Bijlsma W; Willers J
    Cell Immunol; 1979 Aug; 46(1):187-91. PubMed ID: 487442
    [No Abstract]   [Full Text] [Related]  

  • 6. Complement-dependent B-cell activation by cobra venom factor and other mitogens?
    Dukor P; Schumann G; Gisler RH; Dierich M; König W; Hadding U; Bitter-Suermann D
    J Exp Med; 1974 Feb; 139(2):337-54. PubMed ID: 4589989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific Lyt 123 cells are involved in protection against Listeria monocytogenes and in delayed-type hypersensitivity to listerial antigens.
    Kaufmann SH; Simon MM; Hahn H
    J Exp Med; 1979 Oct; 150(4):1033-8. PubMed ID: 117073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cobra venom factor: evidence for its being altered cobra C3 (the third component of complement).
    Alper CA; Balavitch D
    Science; 1976 Mar; 191(4233):1275-6. PubMed ID: 56780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of immune response to Listeria monocytogenes: mechanism(s) of immune complex suppression.
    Virgin HW; Wittenberg GF; Bancroft GJ; Unanue ER
    Infect Immun; 1985 Nov; 50(2):343-53. PubMed ID: 3932204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic restriction in the rat: genetic basis of restriction of the T cell mediators of delayed-type hypersensitivity and antimicrobial resistance to Listeria monocytogenes.
    Jungi TW; McGregor DD
    J Immunogenet; 1980 Jun; 7(3):243-60. PubMed ID: 6774028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement depletion with humanised cobra venom factor: efficacy in preclinical models of vascular diseases.
    Vogel CW; Fritzinger DC; Gorsuch WB; Stahl GL
    Thromb Haemost; 2015 Mar; 113(3):548-52. PubMed ID: 25031089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flare-up of antigen-induced arthritis in mice after challenge with intravenous antigen: effects of pre-treatment with cobra venom factor and anti-lymphocyte serum.
    Lens JW; van den Berg WB; van de Putte LB; Berden JH; Lems SP
    Clin Exp Immunol; 1984 Sep; 57(3):520-8. PubMed ID: 6235993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of complement depletion on corneal inflammation in rats.
    Verhagen C; Breebaart AC; Kijlstra A
    Invest Ophthalmol Vis Sci; 1992 Feb; 33(2):273-9. PubMed ID: 1740355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparin and derivatized heparin inhibit zymosan and cobra venom factor activation of complement in serum.
    Edens RE; Linhardt RJ; Bell CS; Weiler JM
    Immunopharmacology; 1994; 27(2):145-53. PubMed ID: 8014028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of C5 by cobra venom factor is required in neutrophil-mediated lung injury in the rat.
    Till GO; Morganroth ML; Kunkel R; Ward PA
    Am J Pathol; 1987 Oct; 129(1):44-53. PubMed ID: 3661679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The oligosaccharide chains of cobra venom factor are required for complement activation.
    Grier AH; Vogel CW
    Mol Immunol; 1989 Jun; 26(6):563-74. PubMed ID: 2770749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hybrid proteins of Cobra Venom Factor and cobra C3: tools to identify functionally important regions in Cobra Venom Factor.
    Hew BE; Wehrhahn D; Fritzinger DC; Vogel CW
    Toxicon; 2012 Sep; 60(4):632-47. PubMed ID: 22609532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors in cobra venoms affecting the complement system.
    Vogt W
    Toxicon; 1982; 20(1):299-303. PubMed ID: 7080043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humanized cobra venom factor: experimental therapeutics for targeted complement activation and complement depletion.
    Vogel CW; Fritzinger DC
    Curr Pharm Des; 2007; 13(28):2916-26. PubMed ID: 17979736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antilymphocytic antibodies and marrow transplantation. XIV. Antibody-induced suppression of graft-versus-host disease in C3-decomplemented mice differentiates two T-cell-depletion pathways.
    Thierfelder S; Mysliwietz J; Hoffmann-Fezer G; Kummer U
    Blood; 1991 May; 77(10):2285-91. PubMed ID: 2029584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.